Nexera Pharmaceuticals Inc. was established in August 2018. The company has expertise in areas such as rheumatology, neurology, and auto-immune diseases. Some of our notable products includes Metoject and Oralvisc. Specializing in rheumatology, hematology and oncology, we are also providing advanced therapeutics for the treatment of cancer and autoimmune diseases. Nexera Pharmaceuticals inc, are also engaged in numerous commercial agreements with partners in Canada and other countries. We have a strong North American commercial platform and we currently operate through two unique segments: Nexera Pharma Canada and Nexera Pharma USA.